TY - JOUR
T1 - Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group
AU - Sakai, Tomoyuki
AU - Masaki, Yasufumi
AU - Otsuki, Nozomi
AU - Sakamaki, Ippei
AU - Kishi, Shinji
AU - Miyazono, Takayoshi
AU - Urasaki, Yoshimasa
AU - Murakami, Jun
AU - Satoh, Tomomi
AU - Nakamura, Takuji
AU - Iwao, Haruka
AU - Nakajima, Akio
AU - Kawanami, Takafumi
AU - Miki, Miyuki
AU - Fujita, Yoshimasa
AU - Tanaka, Masao
AU - Fukushima, Toshihiro
AU - Okazaki, Toshiro
AU - Ueda, Takanori
N1 - Publisher Copyright:
© 2015, The Author(s).
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a combination regimen of rituximab, cladribine, mitoxantrone, and dexamethasone (R-CMD) in indolent B cell lymphoma and MCL. A total of 33 CD20-positive patients who received care between January 2008 and August 2011 were investigated. These patients’ illnesses were FL (n = 21), nodal marginal zone B cell lymphoma (NMZB, n = 3), MCL (n = 3), splenic marginal zone B cell lymphoma (n = 2), hairy cell leukemia (n = 1), Waldenstrom macroglobulinemia (WM, n = 1), and lymphoplasmacytic lymphoma (LPL, n = 2). Patients received four 21-day cycles of rituximab 375 mg/m2 (day 1), cladribine 0.10 mg/kg (days 1–3), mitoxantrone 8 mg/m2 (day 1), and dexamethasone 8 mg/body (days 1–3), with four additional rituximab doses at 4-week intervals. Of the 33 patients, 26 achieved complete response/unconfirmed complete response, and six achieved a partial response (4 with FL, 1 with NMZB, 1 with WM). One had progressive disease (FL), and four relapsed after remission (1 with FL, 2 with MCL, 1 with LPL). R-CMD therapy was relatively convenient and effective in indolent B cell lymphoma and MCL. Nonetheless, to suppress the number and function of both B cells and T cells, comprehensive infection prevention and follow-up are necessary in the future.
AB - Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a combination regimen of rituximab, cladribine, mitoxantrone, and dexamethasone (R-CMD) in indolent B cell lymphoma and MCL. A total of 33 CD20-positive patients who received care between January 2008 and August 2011 were investigated. These patients’ illnesses were FL (n = 21), nodal marginal zone B cell lymphoma (NMZB, n = 3), MCL (n = 3), splenic marginal zone B cell lymphoma (n = 2), hairy cell leukemia (n = 1), Waldenstrom macroglobulinemia (WM, n = 1), and lymphoplasmacytic lymphoma (LPL, n = 2). Patients received four 21-day cycles of rituximab 375 mg/m2 (day 1), cladribine 0.10 mg/kg (days 1–3), mitoxantrone 8 mg/m2 (day 1), and dexamethasone 8 mg/body (days 1–3), with four additional rituximab doses at 4-week intervals. Of the 33 patients, 26 achieved complete response/unconfirmed complete response, and six achieved a partial response (4 with FL, 1 with NMZB, 1 with WM). One had progressive disease (FL), and four relapsed after remission (1 with FL, 2 with MCL, 1 with LPL). R-CMD therapy was relatively convenient and effective in indolent B cell lymphoma and MCL. Nonetheless, to suppress the number and function of both B cells and T cells, comprehensive infection prevention and follow-up are necessary in the future.
KW - Indolent B cell lymphoma
KW - Mantle cell lymphoma
KW - R-CMD
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84958180346&partnerID=8YFLogxK
U2 - 10.1007/s12032-015-0677-9
DO - 10.1007/s12032-015-0677-9
M3 - 学術論文
C2 - 26275804
AN - SCOPUS:84958180346
SN - 1357-0560
VL - 32
SP - 1
EP - 6
JO - Medical Oncology
JF - Medical Oncology
IS - 9
M1 - 232
ER -
